|1.||Gillies, Stephen D: 4 articles (12/2011 - 11/2004)|
|2.||Waldmann, Thomas A: 4 articles (01/2007 - 12/2003)|
|3.||Sachs, David H: 3 articles (08/2015 - 05/2013)|
|4.||Wang, Zhirui: 3 articles (08/2015 - 05/2013)|
|5.||Huang, Christene A: 3 articles (08/2015 - 05/2013)|
|6.||Zhang, Huiping: 3 articles (08/2015 - 05/2013)|
|7.||Waldmann, T A: 3 articles (03/2015 - 05/2000)|
|8.||Dang, Nam H: 3 articles (01/2015 - 10/2004)|
|9.||Roifman, Chaim M: 3 articles (10/2014 - 08/2006)|
|10.||Signore, Alberto: 3 articles (10/2012 - 10/2004)|
10/01/2011 - "The value of soluble IL-2 receptor antibody was 16,000U/ml. Intravascular lymphoma was suspected because of brain CT finding and IL-2 receptor antibody titer. "
02/01/2009 - "Soluble IL-2 receptor was elevated and malignant lymphoma was clinically diagnosed. "
11/01/2005 - "Measurement of IL-2 receptor and biopsy with flow cytometry were necessary to work out the treatment strategy of the spinal malignant lymphoma. "
05/23/2000 - "Immunogold staining and electron microscopy show that IL-2 receptor alpha-subunits exhibit nonrandom surface distribution on human T lymphoma cells. "
07/15/1995 - "Functional interleukin-2 receptors are expressed on natural killer-like leukemic cells from a dog with cutaneous lymphoma."
11/01/1996 - "IL-2-dependent clones established from the DN alphabeta T cell population in the PEC of IL-2 receptor alpha-chain transgenic B6 mice exhibited potent cytotoxicity against a series of B cell lineage leukemias and myelomas, such as CD5+BCL1 and MOPC, without affecting NK-susceptible targets. "
02/01/1994 - "This report describes that PHA, in vitro, induces the p55 IL-2 receptor subunit on initially p55-negative B-CLL cells and converts toxin-insensitive leukemia cells to a toxin-sensitive state."
11/01/1989 - "MT-1 and HUT-102 cell lines derived from patients with ATL were compared with Molt-4, a leukemia cell line that does not express IL-2 receptors in an uninduced state. "
01/01/1989 - "[Autoimmune reactions against interleukin-2 receptors in patients with blood system diseases and in experimental Rauscher retrovirus leukemia]."
01/01/1985 - "Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression."
|3.||Hodgkin Disease (Hodgkin's Disease)
03/01/1998 - "The aim of this study was to assess the prognostic role of soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease (HD) both in the achievement of complete remission (CR) and in predicting disease relapse. "
07/01/2003 - "In addition to soluble interleukin 2 receptor (sIL-2R) levels, CRP holds promise as a diagnostic and prognostic index and follow-up monitor in pediatric and adolescent patients with Hodgkin disease, and merits further investigation."
03/01/1998 - "Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications."
01/21/1992 - "We have shown that the major contributory factor to the inhibitory effect of sera from patients with Hodgkin's disease (HD) could be the soluble form of Interleukin-2 receptors (sIL-2R). "
03/01/1990 - "Affinity of IL-2 receptors and proliferation of mitogen activated lymphocytes in Hodgkin's disease."
|4.||Hematologic Neoplasms (Hematological Malignancy)
07/15/1995 - "Further, this case illustrates the potential for the use of hematopoietic malignancies in the dog as a suitable animal model for immune targeting of IL-2 receptors as a novel treatment approach for similar malignancies of human beings."
09/01/1993 - "In some conditions, including certain malignant hematologic neoplasms, serum soluble interleukin 2 receptor levels (SIL2R) correlate with disease activity. "
05/15/1989 - "In contrast to these results, most cell lines established from hematopoietic malignancies do not express either chain of the IL-2 receptor. "
05/01/1988 - "The explanation for the expression of the IL-2 receptor by such a variety of different hematologic malignancies remains unclear."
05/15/1992 - "In the first clinical trial of a genetically engineered ligand fusion-toxin, we have treated 18 patients with chemotherapy-resistant IL-2 receptor expressing hematologic malignancies with escalating doses of DAB486IL-2. "
12/01/2006 - "In order to reduce normal cell binding, they were modified by preincubation with a recombinant bispecific protein which blocks the viral native cell binding site and introduces a new binding site for a tumor-associated target (in this study, the interleukin-2-receptor, IL-2R). "
12/01/1997 - "However, the yields are still too low to permit the production of material for clinical trials in which the dsFv will be used to image or treat IL2 receptor (CD25)-containing tumors. "
01/01/1994 - "Study of peripheral blood lymphocyte subset distribution and IL-2 receptor (IL-2 R) p55-p75 subunit expression in patients with cancer of different sites."
09/01/1993 - "The correlation of additional variables such as specific activity of DAB486IL-2 and tumor expression of the p75 subunit of the IL-2 receptor and receptor function will also require further study."
06/01/1993 - "The aim of the investigation was to directly study the IL 2 receptor (IL 2 R) and its subunits, p55 and p75 chains, either membrane-bound or soluble, on peripheral blood mononuclear cells (PBMC) of patients with solid malignancies and, indirectly, the same patients' PBMC ability to produce IL 2. Fifty-eight cancer patients, 29 men and 29 women, were studied: their mean age was 57.3 years, range 35-79. "
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||HLA-DR Antigens (HLA-DR)
|4.||Interleukin-6 (Interleukin 6)
|1.||Drug Therapy (Chemotherapy)
|4.||Renal Dialysis (Hemodialysis)
|5.||Homologous Transplantation (Allograft)